Capricor Therapeutics（股票代码：CAPR）的股价在盘前交易中遭遇重挫，跌幅高达60%。这一暴跌的直接导火索，源于美国食品药品监督管理局（FDA）内部工作人员的审查报告。该报告明确指出，公司针对杜氏肌营养不良症（Duchenne）开发的细胞疗法，其所提交的数据并未能提供显著的疗效证据。
Capricor Therapeutics（股票代码：CAPR）的股价在盘前交易中遭遇重挫，跌幅高达60%。这一暴跌的直接导火索，源于美国食品药品监督管理局（FDA）内部工作人员的审查报告。该报告明确指出，公司针对杜氏肌营养不良症（Duchenne）开发的细胞疗法，其所提交的数据并未能提供显著的疗效证据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.